Mazdutide

Transforming from Regional Leader to Global Premier: A Clear Strategic Path for Growth and Globalization SAN FRANCISCO and SUZHOU, China, Aug. 25, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announces its 2026 interim results and 2030 strategic vision. Dr. Michael Yu, Founder, Chairman of the Board and CEO of Innovent, stated: "Looking back over the past fifteen years, Innovent has completed two key transformations: from 2016 to 2020, we transformed from an R&D-driven biotech company into a biopharmaceutical company with full-value-chain capabilities spanning R&D, manufacturing, and commercialization; from 2021 to 2025, we progressed from a long-term investment phase into a biopharmaceutical company that achieved revenue over RMB 10 billion and full-scale profitability. 2026 marks Innovent's best strategic window to date, and it is against this backdrop that we have set forth our new strategic goals for 2030. We have both the resolve and the confidence to drive our third critical transformation: evolving from a regional leading biopharmaceutical company into a global premier biopharma with global business operational capabilities. In the first half of 2026, Innovent delivered strong growth in both revenue and profit, further reinforcing our leading position in China's biopharmaceutical industry and highlighting our scarce value in both certainty and growth potential. At the same time, over the past ten months, we have reached multiple strategic collaborations with global multinational pharmaceutical leaders including Takeda, Eli Lilly, and Pfizer, while also partnering with biotechs such as Ollin and Spero to advance the global development of our differentiated pipeline. Our partnered pipeline now spans more than 20 assets, including 5 co-development and co-commercialization ("Co-Co") programs, with an aggregate deal value reaching USD 34 billion, representing more than 30% of the total out-licensing value among Chinese pharmaceutical companies over the same period1. Innovent stands at the most favorable strategic window in its development. We will continue to pursue high-quality growth in revenue and profit, guided by clear strategy and disciplined execution — strengthening and amplifying our 'dual-engine' advantage across oncology and general biomedicine, accelerating our global expansion, and advancing toward our 2030 strategic goals, so as to continue creating long-term value for our shareholders and society." A Visible Growth Path: Scale and Profitability Advancing in Parallel In the first half of 2026, Innovent reached RMB 8.6 billion in total revenue, representing 45% year-over-year growth, while product revenue reached RMB 8.2 billion, up 57% year over year. Building on the RMB 10 billion-plus revenue scale, Innovent maintained strong growth momentum, with its dual-engine strategy of oncology and general biomedicine continuing to deliver. Rapid revenue growth, coupled with continued improvements in operational efficiency, further drove improvements in profitability. IFRS net profit for the first half of the year was approximately RMB 1.3 billion, representing approximately 50% year-over-year growth, while Non-IFRS net profit reached RMB 1.7 billion, up 41% year over year. Innovent has entered a new stage characterized by simultaneous expansion in scale and improvement in earnings quality, setting a new paradigm for high-quality growth among biopharmaceutical companies. As of July 31, 2026, Innovent held RMB 30.2 billion in cash reserves, equivalent to approximately US$4.5 billion. In addition, we continued to generate positive cash flow, providing a strong financial foundation for long-term growth. Vision 2030: From China Leader to Global Premier Biopharma Building on high-quality growth and systematic portfolio development, the Company has underpinned its 2030 development goals. Revenue Scale: By 2030, we target to achieve total revenue of RMB 35–40 billion, largely driven by organic expansion from the existing business and pipeline. Sustainable Profitability: By 2030, we aim to benchmark our profit margin to top-tier pharmaceutical companies, through continued revenue expansion and efficiency improvements. Global Innovation: By 2030, we aim to advance at least five molecules into global MRCT Phase 3 development, achieve product launches in key markets, i.e. U.S. and Europe with international revenue emerging. Globalization: building global infrastructure and business operating capabilities, truly transforming into a global premier biopharmaceutical company. From "Product-led Growth" to "Portfolio-Driven Growth," with Dual Growth Engines Unleashing New Momentum China's Leading Oncology Franchise: Strengthening Core Oncology Leadership While Expanding Strategically into Key Growth Areas In oncology, Innovent has established a strong product portfolio and brand presence across core indications including lung cancer, gastrointestinal cancers and hematological malignancies. Focusing on the next-generation "IO + ADC" innovation strategy, the Company is advancing next-generation assets including IBI363 (PD-1/IL-2α-biased), IBI343 (CLDN18.2 ADC), and IBI3003 (GPRC5D/BCMA/CD3) into late-stage clinical development, establishing long-term growth drivers and competitive advantages across multiple strategic areas. Meanwhile, through its collaboration with Lilly on Verzenio® (abemaciclib) in breast cancer, we have strategically gained an important entry point into this major high-incidence tumor type. This asset lays the foundation for upcoming in-house pipeline programs such as IBI354(HER2 ADC) and IBI3014(PD-L1/TROP2 ADC), and paves the way for a more systematic presence in breast cancer. General Biomedicine Franchise Emerged as a New Growth Engine In general biomedicine, Innovent has established a clear framework across four major chronic disease areas—metabolic, cardiovascular, ophthalmology and autoimmune—and this franchise has become another core pillar of Innovent. SYCUME® (Teprotumumab, IGF-1R antibody), China's first innovative therapy for thyroid eye disease in 70 years; Mazdutide, the world's first and only approved GCG/GLP-1 dual-receptor agonist for obesity and type 2 diabetes; and SINTBILO® (tafolecimab injection), the first China-domestic PCSK9 inhibitor included in the NRDL—all exhibited robust performance. PECONDLE® (picankibart injection, IL-23p19 antibody), the anchor asset in autoimmune diseases, was also approved at the end of 2025. At the same time, our next‑generation metabolic and obesity pipeline – including IBI3032 (once‑daily oral GLP‑1), IBI3042 (once‑weekly oral GLP‑1), IBI3040 (Amylin), IBI3046 (INHBE siRNA) and IBI3030 (monthly PCSK9‑GGG) – provides deep, long‑term growth reserves in global obesity and metabolic disease. In cardiovascular & metabolism, autoimmune and ophthalmology, we are following a "flagship products life cycle management + next‑generation innovation" strategy to build focused product clusters and durable competitive positions in each area. Three Late-Stage Global Assets Unlocking More Than US$60 Billion Total Addressable Market (TAM), and 20+ Partnered Programs Accelerating Global Innovation Innovent is advancing global development of its core assets through multiple collaboration models. Three key assets have entered, or are about to enter, global multi-regional Phase 3 trials, with a combined addressable market estimated at over US$60 billion, and are expected to be major value drivers in the coming years: IBI363 (PD-1/IL-2α-biased, Takeda R&D Code: TAK-928): Next-gen IO cornerstone, potential TAM over US$40 billion for first wave of indications, global co-development with Takeda A global multi-regional Phase 3 study (MarsLight-11) in IO-resistant squamous non-small cell lung cancer (NSCLC) is ongoing, and with expansion into IO-resistant non-squamous NSCLC in preparation. A pivotal Phase 2 study of IBI363 in melanoma in China is expected to read out in the second half of 2026, potentially supporting the first NDA submission for IBI363. IBI363 has demonstrated preliminary positive PoC results in first-line NSCLC. PoC studies in first-line NSCLC and first-line colorectal cancer are ongoing, with additional PoC studies being advanced across other tumor types, further supporting its potential as a next-generation IO backbone therapy. Arcotatug Tavetecan (CLDN18.2 ADC, Innovent/Takeda R&D Code: IBI343/TAK-921): Globally First NDA stage Next-Generation Fc-Silenced CLDN18.2 ADC, potential TAM over US$8 billion The China-Japan multicenter Phase 3 study completed its first interim analysis and achieved primary endpoint. The NDA submission has been accepted by NMPA for the treatment of CLDN18.2-positive advanced gastric cancer in later-line settings. A Phase 3 study in first-line pancreatic cancer is planned to initiate in China. International multicenter Phase 1 and PoC studies in first-line pancreatic cancer and first-line gastric cancer are ongoing. IBI324 (VEGF/ANG2, Ollin R&D Code: OLN324): Potential best-in-disease retinal therapy, potential TAM US$15 billion Our partner Ollin Biosciences reported positive results from the Phase 1b JADE head-to-head study against faricimab in nAMD and DME patients in the U.S. Ollin plans to initiate global multi-regional Phase 3 studies in DME and nAMD in the second half of 2026, and through collaboration with Innovent, to conduct patient enrollment in China and South Korea. Diversified Partnerships to Accelerate Global Innovation Over the past 10 months, Innovent has entered into strategic multi-product collaborations with global multi-national pharmaceutical companies including Takeda, Lilly and Pfizer, while partnering with biotech companies such as Ollin and Spero to rapidly validate differentiated pipeline programs in selected disease areas. The aggregate deal value reaching US$34 billion, covering more than 20 pipeline programs, among which five are "Co-Co" assets. Leveraging diversified partnership models, the Company will progressively build overseas R&D and commercialization capabilities and evolve into a truly world-class biopharmaceutical company with global business operating capabilities. High-Quality Manufacturing Standards Innovent operates advanced manufacturing facilities built to international standards and our Suzhou manufacturing site has recently undergone and successfully passed a Good Manufacturing Practice (GMP) inspection conducted by the European Medicines Agency (EMA), and has obtained the corresponding GMP certificate. Total operational capacity of 140,000 liters, accounting for 20% of China's total biologic manufacturing capacity. Suzhou site houses 60,000 liters of antibody capacity and ADC commercial lines; Hangzhou site has 80,000 liters of antibody capacity, supporting global supply and CDMO services. Sustainable Development and ESG Commitment 9,000 employees worldwide, with global R&D centers in San Francisco Bay Area, Shanghai and Suzhou. Over 3,000 new cancer patients initiate Innovent therapies daily; more than 10 million patients have benefited to date. Maintained MSCI ESG AAA rating, leading China's biopharmaceutical industry. First innovative biopharma constituent of the Hang Seng Index ("blue-chip" status). Launched community health initiatives including the MV 'Weight Management Made Easy' and documentary 'Down in Weight, Up in Life' to promote science-based healthy weight management. Published patient education materials on thyroid eye disease and weight management to enhance public health awareness. Implemented multiple patient assistance programs, benefiting over 200,000 patients with drug donations valued at over RMB 4 billion. Received honors including "Healthcare Public Welfare Pioneer" and "China Public Welfare Enterprise". Created over 2,700 jobs for new graduates. Cumulative taxes and contributions exceeding RMB 9 billion. Note: Data source: Next Pharma database. About Innovent Biologics Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 20 products in the market. It has 1 asset in NMPA NDA review, 5 assets in Phase 3 or pivotal clinical trials and 14 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Lilly, Takeda, Pfizer, Roche, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action" Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit , or follow Innovent on Facebook and LinkedIn. Statement: 1) Innovent does not recommend the use of any unapproved drug (s)/indication (s). 2) Ramucirumab (Cyramza) and Selpercatinib (Retsevmo), Pirtobrutinib (Jaypirca) and abemaciclib (Verzenios) were developed by Eli Lilly and Company. Disclaimer: Innovent does not recommend any off-label usage. Forward-Looking Statements of Innovent Biologics This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions. SOURCE Innovent Biologics 21% more press release views with Request a Demo

近日，在火热召开的中华医学会第二十三次内分泌学学术会议（CSE 2026）上，《肥胖患者的长期体重管理及药物临床应用指南（2026版）》（以下简称《2026版肥胖指南》）与《多靶点肠促胰素受体激动剂在代谢相关共病管理中的应用专家共识》（以下简称《多靶点共识》）两部重磅指南同步发布，成为本届会议的热点。 图1 大会现场 《2026版肥胖指南》 迭代升级，构建中国特色长期体重管理体系 《2026版肥胖指南》由中华医学会内分泌学分会肥胖学组牵头组织，联合国内各肥胖相关专业学科专家共同制订，其中，曲伸教授( 同济大学附属第十人民医院)、赵家军教授( 山东第一医科大学附属省立医院) 、王卫庆教授( 上海交通大学医学院附属瑞金医院)为通讯作者。本次指南在2024版指南的基础上进行了多维度评估、个体化减重目标设定、长期体重管理、减重后体重维持等更新升级 [1]。 首先该指南更新了多维度评估体系，明确最佳体重不只是BMI正常化，需综合BMI、腰围、腰高比、体脂率、内脏脂肪共同判定，特别强调针对BMI正常但腹型肥胖人群，必须结合腰围、腰高比综合评估诊断[1]。在此基础上，该指南明确长期体重管理的目的在于实现个体化最佳体重并长期维持，以降低肥胖相关并发症风险或控制已有并发症进展，提高整体生活质量和健康状况；长期体重管理遵循及时、长期、个体三大原则，体重管理关口前移，包括早期起始体重管理、早期联合药物干预，并采取治疗达标策略、制定长期体重管理计划[1]。 在长期体重管理的框架下，长期药物体重管理是其重要的治疗手段，玛仕度肽作为全球首个且唯一获批的GCG/GLP-1双受体激动剂被纳入其中，指南明确指出GCG受体激动可促进脂肪分解和脂肪酸氧化，对能量消耗具有有利作用。GCG与GLP-1可协同减少食物摄入，并增加能量消耗。GLORY-1研究显示，玛仕度肽6mg 治疗48周 体重较基线下降14.84%，腰围较基线下降10.96cm，总脂肪含量减少24.73%； GLORY-2研究显示，玛仕度肽9mg治疗60周后，平均减重18.55%。为肥胖患者，尤其是腹型肥胖带来重要选择。 此外，《2026版肥胖指南》专设“长期用药在减重后体重维持中的核心地位”章节[1]，指出减重后的体重维持即预防反弹，是长期体重管理中最具挑战的环节。 并对于药物强化治疗后减重达标或达到个体最大减重幅度的患者，给出五种维持方案： 维持原有减重药和生活方式干预不变 减少药物剂量或延长给药间隔 调整为更便捷的减重药 单纯生活方式干预或合并间断性用药 必要时选择减重手术 《2026版肥胖指南》也更加关注在肥胖患者减重外的其他代谢获益，指南指出，肥胖与多系统疾病密切相关，减重可改善甚至逆转多种合并症；由于 78% 的患者就诊时已合并至少一种肥胖相关合并症，减重药物的选择应充分考虑患者的具体情况，优先选择兼具相应合并症获益的药物。其中特别指出玛仕度肽6mg治疗48周，在基线肝脏脂肪含量(LFC)≥10%的超重肥胖患者中，LFC下降达80.2%。且同时具有降低血压、血脂、血尿酸等多重获益。 《多靶点肠促胰素受体激动剂在代谢相关共病管理中的应用专家共识》 精准赋能，共病管理一体化 《多靶点共识》立足中国人群常在较低BMI（≥24 kg/m²）即出现腹型肥胖、内脏脂肪蓄积和MASLD等代谢特征，指出单纯依赖BMI可能低估代谢风险，启动药物治疗前应同时评估腰围、血糖、血脂、肝酶、肝脏脂肪含量和心肾风险[2]。整体诊疗趋势从单纯降糖减重转向糖、脂、肝、肾、心多系统一体化共病管理，引入CKM综合征概念，将治疗目标从体重和HbA1c扩展至综合风险管理（图2）。 图2《多靶点共识》部分推荐意见 《多靶点共识》明确了GCG/GLP-1双受体激动剂的作用机制和临床优势。GCG/GLP-1双受体激动剂通过GCG通路提高基础代谢率、加速肝脏脂肪酸β氧化和内脏脂肪动员，对腹型肥胖和MASLD高负担人群具有机制优势[2]。 DREAMS系列和GLORY系列研究在中国成人T2DM和肥胖人群中积累了GCG/GLP-1双受体激动剂玛仕度肽的临床数据[2]。此外，研究还证实玛仕度肽治疗在减重、降糖、使肝脏脂肪含量大幅降低的同时，血尿酸水平显著降低，有助于临床对高尿酸血症和痛风的干预管理（图3）[2]。 图3《多靶点共识》部分推荐意见 在分层用药逻辑方面，共识提出：初诊时即存在T2DM合并肥胖、MASLD、腹型肥胖等多重代谢共病特征的患者，可直接评估是否首选多靶点药物；单靶点GLP-1RA经足量足疗程（3~6个月）后血糖或体重仍未达标者，可升级至多靶点药物。共识同时给出标准化剂量滴定、药物转换方案，并着重强调停药会出现明显体重反弹——SURMOUNT-4数据显示停药后1年内体重反弹约占减重量的55%，因此建议达到阶段性目标后不建议自行停药，需长期药物维持[2]。 玛仕度肽 两大指南共同推荐的本土创新双靶点药物 玛仕度肽是全球首个获批的GCG/GLP-1双受体激动剂，于2025年在我国获批长期体重管理适应证。其GLP-1通路控制食欲与血糖，GCG通路促进能量消耗和肝脏脂质氧化，两者协同实现减重与代谢获益的同时维持血糖稳定。GCG通路直接促进肝脏脂肪酸β氧化和脂肪分解——这一肝脏脂质代谢直接改善作用是玛仕度肽区别于其他多靶点药物的核心机制特征，也是共识推荐含GCG通路药物用于MASLD/MASH管理的机制依据。 当前，玛仕度肽已有丰富的临床数据。 减重证据方面： 中国Ⅲ期临床试验GLORY-1纳入中国无T2DM的超重或肥胖成人，48周时6 mg组体重下降14.01%，81.6%的受试者体重下降≥5%，49.5%下降≥15%；肝脏脂肪含量≥10%的患者中，肝脏脂肪降幅达80.2%。 GLORY-2探索了9 mg高剂量，60周时体重下降18.55%，无T2DM亚组减重达20.08%，48.7%实现20%及以上减重幅度，腰围显著缩小达14cm，颈围缩小3cm 降糖证据方面： DREAMS-1显示玛仕度肽6 mg在24周时使HbA1c下降2.02%，HbA1c <7.0%达标率为81.8%。 DREAMS-2显示玛仕度肽6 mg对比度拉糖肽1.5 mg在HbA1c降幅方面显著更优（-1.66% vs -1.36%），体重下降更显著（-8.53% vs -2.77%）。 DREAMS-3头对头研究中，玛仕度肽6 mg对比司美格鲁肽1 mg的复合终点（HbA1c <7.0%且体重下降≥10%）达标率为48.0% vs 21.0%（P<0.0001），HbA1c降幅-2.03% vs -1.84%，体重降幅-10.29% vs -6.00%，且在降低转氨酶和肝脏脂肪含量方面显著优于司美格鲁肽。  此外，玛仕度肽在HFpEF、OSA、MASH、MASLD、青少年、高血压等领域的RCT正在进行中，结果将进一步拓展其临床应用场景。而在安全性方面，玛仕度肽总体耐受性良好，不良反应多为轻中度，胃肠道反应最常见于起始和递增阶段，剂量稳定后减轻。 结语 玛仕度肽作为全球首个且唯一获批的GCG/GLP-1双受体激动剂，凭借扎实的中国人群临床循证数据，成功获得两部指南纳入与推荐。其强效减重、燃脂护肝、全面代谢获益的优势精准匹配中国人群腹型肥胖与代谢共病高发的特征，为中国肥胖患者长期体重管理与肥胖相关代谢共病管理注入了强劲的中国创新力量。 声明：本文旨在为医疗卫生专业人士传递更多医学信息，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，信达不推荐任何未获批的药品/适应症使用。个体存在身体差异，如有健康问题，请及时就医，谨遵医嘱。 参考文献： 1.中华医学会内分泌学分会. 肥胖患者的长期体重管理及药物临床应用指南(2026版)[J]. 中华内分泌代谢杂志, 2026, 42(08)：641-669. DOI:10.3760/cma.j.cn311282-20260512-00213 2.AMERICAN DIABETES ASSOCIATION PROFESSIONAL PRACTICE COMMITTEE FOR OBESITY. Pharmacologic treatment of obesity in adults: Standards of care in overweight and obesity‑2026[J]. BMJ Open Diabetes Research & Care, 2026, 13(Suppl 1): e005729. doi:10.1136/bmjdrc‑2025‑005729. 3.中华医学会内分泌学分会. 多靶点肠促胰素受体激动剂在代谢相关共病管理中的应用专家共识[J]. 中华内分泌代谢杂志, 2026, 42(08)：733-744. DOI:10.3760/cma.j.cn311282-20260602-00259 关于信达生物 - 滑动查看更多介绍 - "始于信，达于行"，开发出老百姓用得起的高质量生物药，是信达生物的使命和目标。信达生物成立于2011年，致力于研发、生产和销售肿瘤、自身免疫、代谢、眼科等重大疾病领域的创新药物，让我们的工作惠及更多的生命。公司已有20个产品获得批准上市，它们分别是信迪利单抗注射液（达伯舒®），贝伐珠单抗注射液（达攸同®），阿达木单抗注射液（苏立信®），利妥昔单抗注射液（达伯华®），佩米替尼片（达伯坦®），奥雷巴替尼片（耐立克®）， 雷莫西尤单抗注射液（希冉择®），塞普替尼胶囊（睿妥®），伊基奥仑赛注射液（福可苏®），托莱西单抗注射液（信必乐®），氟泽雷塞片（达伯特®），匹妥布替尼片(捷帕力®)，己二酸他雷替尼胶囊（达伯乐®），利厄替尼片（奥壹新®），替妥尤单抗N01注射液（信必敏®），玛仕度肽注射液（信尔美®），匹康奇拜单抗注射液（信美悦®），伊匹木单抗N01注射液（达伯欣®），阿贝西利片（唯择®）和盐酸奎扎替尼片（维复泰®）。目前，还有1个品种在NMPA审评中，5个新药分子进入III期或关键性临床研究，14个新药品种已进入临床研究。 公司已与礼来、罗氏、武田、辉瑞、赛诺菲、Incyte和MD Anderson 癌症中心等国际合作方达成30多项战略合作。信达生物在不断自研创新药物、谋求自身发展的同时，秉承经济建设以人民为中心的发展思想。多年来，始终心怀科学善念，坚守"以患者为中心"，心系患者并关注患者家庭，积极履行社会责任。公司陆续发起、参与了多项药品公益援助项目，让越来越多的患者能够得益于生命科学的进步，买得到、用得起高质量的生物药。截至目前，信达生物患者援助项目已惠及20余万普通患者，药物捐赠总价值40亿元人民币。信达生物希望和大家一起努力，提高中国生物制药产业的发展水平，以满足百姓用药可及性和人民对生命健康美好愿望的追求。 详情请访问公司网站：www.innoventbio.com或公司领英账号：Innovent Biologics。